Mini Oral Session 1: Improvement and Implementation of Lung Cancer Screening

Conference Correspondent - WCLC 2016 - Lung Cancer


Summaries of the following research efforts will be presented during Mini Oral Session 1:

  • Detection of Lung Cancer and EGFR Mutations by Electronic Nose System. Shlomi D, et al. Researchers found that breath analysis could discriminate between lung cancer and benign pulmonary nodules, and between EGFR-positive and -negative mutations. In the future, a portable, inexpensive, simple device may be a viable way to evaluate pulmonary nodules.
  • Non-Invasive LuCED® Test for Endobronchial Dysplasia, Enabling Chemoprevention Therapy with Drugs Such as Iloprost. Meyer M, et al. Identification of endobronchial lung dysplasia with a noninvasive sputum-based test could facilitate chemoprevention. Researchers evaluated a novel test for early-stage lung cancer to learn if it can identify tumor cells that have been exfoliated into sputum. They concluded that the LuCED test can detect endobronchial dysplasia in the lung with an estimated 98% case sensitivity and 95% case specificity.
  • Predictive Performances of NELSON Screening Program Based on Clinical, Metrological and Population Statistics. Beaumont H, et al. Researchers tested a simulation of the NELSON triage algorithm by using published statistics as input data: nodule size distribution, nodule growth distribution, and the precision of nodule volume measurements. They discerned markedly different test performance for size versus growth assessment of the NELSON triage algorithm. Future work is designed to optimize triage algorithms in screening programs.
  • Mortality, Survival and Incidence Rates in the ITALUNG Randomised Lung Cancer Screening Trial (ITALY). Paci E, et al. Low-dose computed tomography (LDCT) screening for lung cancer is not yet recommended in Europe. This long-term study randomized 3206 eligible subjects to receive 4 annual LDCT scans (n = 1613) or usual care (n = 1593). Overall and lung-cancer–specific mortality were reduced by 17% and 30% in the LDCT versus control groups, respectively. Among the lung cancers diagnosed, a greater proportion of those in the LDCT group were stage I.